<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302743</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20110004H</org_study_id>
    <nct_id>NCT01302743</nct_id>
  </id_info>
  <brief_title>Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.</brief_title>
  <official_title>Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin as Initial Treatment for Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mike O'Callaghan Military Hospital</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mike O'Callaghan Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether Cinnamon bark or water-soluble cinnamon is an
      effective nutraceutical for the initial treatment of diabetes when compared to standard
      therapy of Metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are studying whether or not cinnamon bark or water-soluble cinnamon could be an effective
      nutraceutical for the initial treatment of diabetes when compared to standard therapy of
      metformin 1000 mg (extended-release). This study will enroll 309 subjects type 2 diabetics
      (using American Diabetes Association criteria) on no hypoglycemic medications. Subjects will
      be randomized into one of three groups, group 1 will receive oral extended-release Metformin
      1000mg, group 2 will receive Cinnamon Bark 1000mg, group 3 will receive cinnulin PF 500mg.
      Subjects will be instructed to take their study pills once a day for 90 days.After 90 days of
      treatment, each subject will again have hemoglobin A1C, lipid panel, height, weight, blood
      pressure and waist circumference measured. Analysis described above using intention-to-treat
      principles for any missing data will be used (we will use the carry-forward method to impute
      missing data). Subjects will bring in any remaining medication to determine adherence rates
      to the study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recruitment
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in HbA1c</measure>
    <time_frame>90 days</time_frame>
    <description>Subjects will have baseline blood levels to measure HbA1c. Subjects will then take either cinnamon bark powder, water-soluble cinnamon extract or metformin for 90 days then blood levels of HbA1c and lipid panel will be drawn again.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease in LDL Cholesterol</measure>
    <time_frame>90 days</time_frame>
    <description>Subjects will have baseline blood levels to measure LDL Cholesterol. Subjects will then take either cinnamon bark powder, water-soluble cinnamon extract or metformin for 90 days then blood levels of HbA1c and lipid panel will be drawn again.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral extended-release Metformin 1000 mg once a day for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cinnamon Bark</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cinnamon Bark 1000 mg once a day for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cinnulin PF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cinnulin PF 500 mg once a day for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1: Metformin</intervention_name>
    <description>Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Group 2: Cinnamon Bark</intervention_name>
    <description>Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days</description>
    <arm_group_label>Cinnamon Bark</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Group 3: Cinnulin PF</intervention_name>
    <description>Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.</description>
    <arm_group_label>Cinnulin PF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE
        IN ORDER TO PARTICIPATE IN THIS STUDY.

        Inclusion:

          -  Patients 18 years or older.

          -  Diagnosed with type 2 diabetes mellitus within the past 30 days or who have been
             diagnosed and have not begun treatment.

        Exclusion:

          -  Subjects who are &lt;18 yrs of age.

          -  Pregnant or breastfeeding.

          -  Allergic to cinnamon.

          -  Allergic to metformin.

          -  Patients taking metformin are excluded from participating, unless they agree to wash
             out for two weeks prior to entering the study.

          -  Patients taking Cinnamon as a dietary supplement are excluded from participating,
             unless they agree to wash out for two weeks prior to entering the study.

          -  Patients taking any of the following:

               -  Daily oral steroids

               -  Warfarin

               -  Hypoglycemic medication

               -  Weight loss medication

               -  Digoxin, lithium, phenytoin, &amp; theophylline (due to narrow therapeutic indices)

          -  Serum creatinine &gt;1.5 (this is standard of care that would be measured by PCM upon
             diagnosis of type 2 diabetes mellitus)

          -  Initial hemoglobin A1C &gt;9.5(this is standard of care that would be measured by PCM
             upon diagnosis of type 2 diabetes mellitus).

          -  Clinical or laboratory evidence of liver disease.

          -  Clinical or laboratory evidence of Alcoholism.

          -  New York Heart Association (NYHA) Class III and IV congestive heart failure.

               -  Class III: Cardiac disease resulting in marked limitation of physical activity -
                  less than ordinary activity causes fatigue, palpitation, dyspnea, or angina.
                  Comfortable at rest.

               -  Class IV: Cardiac disease resulting in inability to carry on any physical
                  activity without discomfort or symptoms. Symptoms may be present at rest. If any
                  physical activity is undertaken, discomfort or symptoms are increased.

          -  Patients who are known to have or develop during the study any of the following upon
             review of their medical record:

               -  Celiac disease

               -  Insulinoma

               -  Cushings Disease

               -  Hyperthyroidism

               -  Acromegaly

               -  Phechromocytoma

               -  Addison's Disease

               -  Galactosemia

               -  Glycogen storage disease

               -  Hereditary fructose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Crawford, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mike O'Callaghan Federal Hospital/Nellis Air Force Base</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mike O'Callaghan Federal Hospital</name>
      <address>
        <city>Nellis Air Force Base</city>
        <state>Nevada</state>
        <zip>89191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>December 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 28, 2017</results_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Metformin</keyword>
  <keyword>Cinnamon</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>oral extended-release Metformin 1000 mg once a day for 90 days
Group 1: Metformin: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days</description>
        </group>
        <group group_id="P2">
          <title>Cinnamon Bark</title>
          <description>Cinnamon Bark 1000 mg once a day for 90 days
Group 2: Cinnamon Bark: Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days</description>
        </group>
        <group group_id="P3">
          <title>Cinnulin PF</title>
          <description>Cinnulin PF 500 mg once a day for 90 days
Group 3: Cinnulin PF: Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>oral extended-release Metformin 1000 mg once a day for 90 days
Group 1: Metformin: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days</description>
        </group>
        <group group_id="B2">
          <title>Cinnamon Bark</title>
          <description>Cinnamon Bark 1000 mg once a day for 90 days
Group 2: Cinnamon Bark: Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days</description>
        </group>
        <group group_id="B3">
          <title>Cinnulin PF</title>
          <description>Cinnulin PF 500 mg once a day for 90 days
Group 3: Cinnulin PF: Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease in HbA1c</title>
        <description>Subjects will have baseline blood levels to measure HbA1c. Subjects will then take either cinnamon bark powder, water-soluble cinnamon extract or metformin for 90 days then blood levels of HbA1c and lipid panel will be drawn again.</description>
        <time_frame>90 days</time_frame>
        <population>no data was analyzed as study was stopped early due to low recruitment</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>oral extended-release Metformin 1000 mg once a day for 90 days
Group 1: Metformin: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Cinnamon Bark</title>
            <description>Cinnamon Bark 1000 mg once a day for 90 days
Group 2: Cinnamon Bark: Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Cinnulin PF</title>
            <description>Cinnulin PF 500 mg once a day for 90 days
Group 3: Cinnulin PF: Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in HbA1c</title>
          <description>Subjects will have baseline blood levels to measure HbA1c. Subjects will then take either cinnamon bark powder, water-soluble cinnamon extract or metformin for 90 days then blood levels of HbA1c and lipid panel will be drawn again.</description>
          <population>no data was analyzed as study was stopped early due to low recruitment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Decrease in LDL Cholesterol</title>
        <description>Subjects will have baseline blood levels to measure LDL Cholesterol. Subjects will then take either cinnamon bark powder, water-soluble cinnamon extract or metformin for 90 days then blood levels of HbA1c and lipid panel will be drawn again.</description>
        <time_frame>90 days</time_frame>
        <population>no data was analyzed as study was stopped early due to low recruitment</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>oral extended-release Metformin 1000 mg once a day for 90 days
Group 1: Metformin: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Cinnamon Bark</title>
            <description>Cinnamon Bark 1000 mg once a day for 90 days
Group 2: Cinnamon Bark: Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Cinnulin PF</title>
            <description>Cinnulin PF 500 mg once a day for 90 days
Group 3: Cinnulin PF: Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in LDL Cholesterol</title>
          <description>Subjects will have baseline blood levels to measure LDL Cholesterol. Subjects will then take either cinnamon bark powder, water-soluble cinnamon extract or metformin for 90 days then blood levels of HbA1c and lipid panel will be drawn again.</description>
          <population>no data was analyzed as study was stopped early due to low recruitment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>oral extended-release Metformin 1000 mg once a day for 90 days
Group 1: Metformin: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days</description>
        </group>
        <group group_id="E2">
          <title>Cinnamon Bark</title>
          <description>Cinnamon Bark 1000 mg once a day for 90 days
Group 2: Cinnamon Bark: Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days</description>
        </group>
        <group group_id="E3">
          <title>Cinnulin PF</title>
          <description>Cinnulin PF 500 mg once a day for 90 days
Group 3: Cinnulin PF: Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jill M. Clark, MBA/HCM</name_or_title>
      <organization>Mike O'Callaghan Federal Medical Center</organization>
      <phone>702-653-3298</phone>
      <email>jill.clark.3.ctr@us.af.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

